GlassScriptPhysician profile
Danny Woo
NPI 1710989884
$427,050.84
in general payments reported to CMS, 2019-2025
41 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $46K · 2021: $66K · 2022: $66K · 2023: $107K · 2024: $71K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Travel and Lodging: $34K · Food and Beverage: $4,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $160,136.50 |
| Travel and Lodging | $33,893.80 |
| Food and Beverage | $4,129.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $253,964.80 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $164,644.53 | 2019-2024 | Lokelma, Farxiga |
| Amgen INC. | $1,028.47 | 2019-2023 | Otezla, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $817.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $710.94 | 2019-2024 | Leqvio |
| Glaxosmithkline, LLC. | $586.82 | 2019-2024 | Arexvy |
| Vifor Pharma, INC. | $546.68 | 2019-2021 | |
| Horizon Therapeutics Plc | $458.05 | 2019-2021 | |
| Novo Nordisk INC | $387.86 | 2021-2022 | |
| Organogenesis INC. | $330.00 | 2022-2023 | Puraply |
| Bayer Healthcare Pharmaceuticals INC. | $310.05 | 2021 | |
| Esperion Therapeutics, INC. | $304.93 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $286.29 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $196.01 | 2024 | Voquezna |
| Abbvie INC. | $188.78 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.